Literature DB >> 30975380

Fish oil protects the liver from parenteral nutrition-induced injury via GPR120-mediated PPARγ signaling.

Gillian L Fell1, Bennet S Cho1, Duy T Dao1, Lorenzo Anez-Bustillos1, Meredith A Baker1, Prathima Nandivada1, Amy Pan1, Alison A O'Loughlin1, Paul D Mitchell2, Vania Nose3, Kathleen M Gura4, Mark Puder5.   

Abstract

Intravenous fish oil lipid emulsions (FOLE) can prevent parenteral nutrition (PN)-induced liver injury in murine models and reverse PN-induced cholestasis in pediatric patients. However, the mechanisms by which fish oil protects the liver are incompletely characterized. Fish oil is rich in omega-3 fatty acids, which are ligands for the G-protein coupled receptor 120 (GPR120), expressed on hepatic Kupffer cells. This study tested the hypothesis that FOLE protects the liver from PN-induced injury through GPR120 signaling. Utilizing a previously described murine model of PN-induced liver injury in which mice develop steatosis in response to an oral parenteral nutrition diet, FOLE was able to preserve normal hepatic architecture in wild type mice, but not in congenic GPR120 knockout (gpr120-/-) mice. To further characterize the requirement of intact GPR120 for FOLE-mediated hepatic protection, gene expression profiles of key regulators of fat metabolism were measured. PPARγ was identified as a gene that is up-regulated by the PN diet and normalized with the addition of FOLE in wild type, but not in gpr120-/- mice. This was confirmed at the protein expression level. A PPARγ expression array further identified CD36 and SCD1, both down-stream effectors of PPARγ, to be up-regulated in PN-fed wild type mice yet normalized upon FOLE administration in wild type but not in gpr120-/- mice. Together, these results suggest that FOLE protects the liver, in part, through activation of GPR120 and the downstream effectors PPARγ and CD36. Identification of key genetic determinants of FOLE-mediated hepatic protection may provide targets for small molecule-based hepatic protection strategies.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  Fish oil; GPR120; Intestinal failure-associated liver disease; Lipid emulsions; Non-alcoholic fatty liver disease; Omega-3 fatty acids; Peroxisome proliferator-activated receptor-gamma

Year:  2019        PMID: 30975380      PMCID: PMC6642797          DOI: 10.1016/j.plefa.2019.02.003

Source DB:  PubMed          Journal:  Prostaglandins Leukot Essent Fatty Acids        ISSN: 0952-3278            Impact factor:   4.006


  39 in total

1.  Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C.

Authors:  María Eugenia Miquilena-Colina; Elena Lima-Cabello; Sonia Sánchez-Campos; María Victoria García-Mediavilla; Miguel Fernández-Bermejo; Tamara Lozano-Rodríguez; Javier Vargas-Castrillón; Xabier Buqué; Begoña Ochoa; Patricia Aspichueta; Javier González-Gallego; Carmelo García-Monzón
Journal:  Gut       Date:  2011-01-26       Impact factor: 23.059

2.  Effect of fish oil containing parenteral lipid emulsions on neutrophil chemotaxis and resident-macrophages' phagocytosis in rats.

Authors:  Leticia De Nardi; Raquel Bellinati-Pires; Raquel S Torrinhas; Carlos E Bacchi; Victor Arias; Dan L Waitzberg
Journal:  Clin Nutr       Date:  2008-02-04       Impact factor: 7.324

3.  Analyzing real-time PCR data by the comparative C(T) method.

Authors:  Thomas D Schmittgen; Kenneth J Livak
Journal:  Nat Protoc       Date:  2008       Impact factor: 13.491

4.  Omega-3 fatty acid supplementation prevents hepatic steatosis in a murine model of nonalcoholic fatty liver disease.

Authors:  Ian P J Alwayn; Kathleen Gura; Vânia Nosé; Blanca Zausche; Patrick Javid; Jennifer Garza; Jennifer Verbesey; Stephan Voss; Mario Ollero; Charlotte Andersson; Bruce Bistrian; Judah Folkman; Mark Puder
Journal:  Pediatr Res       Date:  2005-01-19       Impact factor: 3.756

5.  Hepatic CD36 downregulation parallels steatosis improvement in morbidly obese undergoing bariatric surgery.

Authors:  E Pardina; R Ferrer; J Rossell; D Ricart-Jané; K A Méndez-Lara; J A Baena-Fustegueras; A Lecube; J Julve; J Peinado-Onsurbe
Journal:  Int J Obes (Lond)       Date:  2017-05-10       Impact factor: 5.095

6.  Peroxisome proliferator-activated receptors gamma reverses hepatic nutritional fibrosis in mice and suppresses activation of hepatic stellate cells in vitro.

Authors:  Jun Yu; Sui Zhang; Eagle S H Chu; Minnie Y Y Go; Rebecca H Y Lau; Junhong Zhao; Chung-Wah Wu; Lixin Tong; Jingmin Zhao; Terence C W Poon; Joseph J Y Sung
Journal:  Int J Biochem Cell Biol       Date:  2010-02-13       Impact factor: 5.085

Review 7.  Fish oil-based lipid emulsions in the treatment of parenteral nutrition-associated liver disease: an ongoing positive experience.

Authors:  Muralidhar H Premkumar; Beth A Carter; Keli M Hawthorne; Kristi King; Steven A Abrams
Journal:  Adv Nutr       Date:  2014-01-01       Impact factor: 8.701

8.  PGC1beta mediates PPARgamma activation of osteoclastogenesis and rosiglitazone-induced bone loss.

Authors:  Wei Wei; Xueqian Wang; Marie Yang; Leslie C Smith; Paul C Dechow; Junichiro Sonoda; Ronald M Evans; Yihong Wan
Journal:  Cell Metab       Date:  2010-06-09       Impact factor: 27.287

9.  Anti-inflammatory and anti-fibrotic profile of fish oil emulsions used in parenteral nutrition-associated liver disease.

Authors:  Alfonso Pastor-Clerigues; Ezequiel Marti-Bonmati; Javier Milara; Patricia Almudever; Julio Cortijo
Journal:  PLoS One       Date:  2014-12-12       Impact factor: 3.240

10.  Proteomics Analysis Reveals an Important Role for the PPAR Signaling Pathway in DBDCT-Induced Hepatotoxicity Mechanisms.

Authors:  Yunlan Li; Xinxin Liu; Lin Niu; Qingshan Li
Journal:  Molecules       Date:  2017-07-06       Impact factor: 4.411

View more
  5 in total

1.  MicroRNA 122 Reflects Liver Injury in Children with Intestinal Failure-Associated Liver Disease Treated with Intravenous Fish Oil.

Authors:  Kara L Calkins; Shanthie Thamotharan; Shubamoy Ghosh; Yun Dai; Sherin U Devaskar
Journal:  J Nutr       Date:  2020-05-01       Impact factor: 4.798

2.  Novel Approaches for Omega-3 Fatty Acid Therapeutics: Chronic Versus Acute Administration to Protect Heart, Brain, and Spinal Cord.

Authors:  Hylde Zirpoli; Chuchun L Chang; Yvon A Carpentier; Adina T Michael-Titus; Vadim S Ten; Richard J Deckelbaum
Journal:  Annu Rev Nutr       Date:  2020-09-23       Impact factor: 11.848

Review 3.  Impact of Parenteral Lipid Emulsion Components on Cholestatic Liver Disease in Neonates.

Authors:  Gregory Guthrie; Douglas Burrin
Journal:  Nutrients       Date:  2021-02-04       Impact factor: 5.717

4.  Dexmedetomidine ameliorates high-fat diet-induced nonalcoholic fatty liver disease by targeting SCD1 in obesity mice.

Authors:  Linfen Tao; Xiaolong Guo; Min Xu; Yumeng Wang; Wenhua Xie; Hong Chen; Mengyao Ma; Xi Li
Journal:  Pharmacol Res Perspect       Date:  2021-02

5.  Regulation of Free Fatty Acid Receptor 4 on Inflammatory Gene Induced by LPS in Large Yellow Croaker (Larimichthys crocea).

Authors:  Mengjiao Wu; Qingfei Li; Kangsen Mai; Qinghui Ai
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.